Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.

We hypothesize that hydrocortisone infusion in severe community-acquired pneumonia attenuates systemic inflammation and leads to earlier resolution of pneumonia and a reduction in sepsis-related complications. In a multicenter trial, patients admitted to the Intensive Care Unit (ICU) with severe community-acquired pneumonia received protocol-guided antibiotic treatment and were randomly assigned to hydrocortisone infusion or placebo. Hydrocortisone was given as an intravenous 200-mg bolus followed by infusion at a rate of 10 mg/hour for 7 days. Primary end-points of the study were improvement in Pa(O(2)):FI(O(2)) (Pa(O(2)):FI(O(2)) > 300 or >/= 100 increase from study entry) and multiple organ dysfunction syndrome (MODS) score by Study Day 8 and reduction in delayed septic shock. Forty-six patients entered the study. At study entry, the hydrocortisone group had lower Pa(O(2)):FI(O(2)), and higher chest radiograph score and C-reactive protein level. By Study Day 8, treated patients had, compared with control subjects, a significant improvement in Pa(O(2)):FI(O(2)) (p = 0.002) and chest radiograph score (p < 0.0001), and a significant reduction in C-reactive protein levels (p = 0.01), MODS score (p = 0.003), and delayed septic shock (p = 0.001). Hydrocortisone treatment was associated with a significant reduction in length of hospital stay (p = 0.03) and mortality (p = 0.009).

[1]  Charles Natanson,et al.  Meta-Analysis: The Effect of Steroids on Survival and Shock during Sepsis Depends on the Dose , 2004, Annals of Internal Medicine.

[2]  Aubrey E. Taylor.  Effect of excessive erythrocytosis on pulmonary vascular smooth muscle mass. , 2004, American journal of respiratory and critical care medicine.

[3]  Mitchell M. Levy,et al.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.

[4]  M. Büchler,et al.  Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome , 1994, The clinical investigator.

[5]  J. Bartlett.  Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia , 2004 .

[6]  J. Dorca,et al.  Molecular Inflammatory Responses Measured in Blood of Patients with Severe Community-Acquired Pneumonia , 2003, Clinical Diagnostic Laboratory Immunology.

[7]  H. Volk,et al.  Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. , 2003, American journal of respiratory and critical care medicine.

[8]  D. Franchimont,et al.  Glucocorticoids and Inflammation Revisited: The State of the Art , 2003, Neuroimmunomodulation.

[9]  F. Keleştimur,et al.  Physiological-dose steroid therapy in sepsis [ISRCTN36253388] , 2002, Critical care.

[10]  G. Chrousos,et al.  Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. , 2002, American journal of respiratory and critical care medicine.

[11]  M. Doğanay,et al.  Physiological-dose steroid therapy in sepsis , 2002 .

[12]  D. Annane,et al.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. , 2002, JAMA.

[13]  Corinne Alberti,et al.  Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study , 2002, Intensive Care Medicine.

[14]  T. van der Bruggen,et al.  Effect of corticosteroids on nuclear factor-&kgr;B activation and hemodynamics in late septic shock , 2001, Critical care medicine.

[15]  J. Briegel,et al.  Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. , 2001, Journal of the American Society of Nephrology : JASN.

[16]  S. Sahn,et al.  Corticosteroids in acute respiratory failure. , 1999, American journal of respiratory and critical care medicine.

[17]  G. Meduri.  An Historical Review of Glucocorticoid Treatment in Sepsis. Disease Pathophysiology and the Design of Treatment Investigation , 1999 .

[18]  A. Torres,et al.  Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. , 1999, Critical care medicine.

[19]  P. Devos,et al.  Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs. , 1999, Chest.

[20]  A. Torres,et al.  Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. , 1999, The European respiratory journal.

[21]  M. Haller,et al.  Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. , 1999, Critical care medicine.

[22]  A. Torres,et al.  Severe community-acquired pneumonia. , 1996, Clinics in chest medicine.

[23]  Y. Kupfer,et al.  HYDROCORTISONE REVERSES REFRACTORY SEPTIC SHOCK , 1999 .

[24]  M. Niederman,et al.  Severe community-acquired pneumonia. Assessment of severity criteria. , 1998, American journal of respiratory and critical care medicine.

[25]  G. Meduri,et al.  Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. , 1998, JAMA.

[26]  P. Bollaert,et al.  Reversal of late septic shock with supraphysiologic doses of hydrocortisone. , 1998, Critical care medicine.

[27]  D. Männel,et al.  Role of NFkappaB in the mortality of sepsis. , 1997, The Journal of clinical investigation.

[28]  D. Männel,et al.  Role of NF k B in the Mortality of Sepsis , 1997 .

[29]  W. Seeger,et al.  Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. , 1996, The European respiratory journal.

[30]  A. Puren,et al.  Patterns of cytokine expression in community-acquired pneumonia. , 1995, Chest.

[31]  F. Stentz,et al.  Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. , 1995, Chest.

[32]  A. Torres,et al.  Community-acquired pneumonia in the intensive care unit. , 1995, Clinics in chest medicine.

[33]  M. Lamy,et al.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.

[34]  V L Yu,et al.  Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. , 1993 .

[35]  P. Marik,et al.  Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. , 1993, Chest.

[36]  P. Lachenbruch,et al.  The Design and Analysis of Sequential Clinical Trials (2nd ed.). , 1993 .

[37]  J. Chastre,et al.  The Standardization of Bronchoscopic Techniques for Ventilator-Associated Pneumonia , 1992, Infection Control &#x0026; Hospital Epidemiology.